127
Participants
Start Date
February 28, 2006
Primary Completion Date
April 30, 2014
Study Completion Date
August 31, 2014
Ablation System plus anti-secretory medication
Treatment group subjects undergo up to 4 ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI).
Sham procedure plus anti-secretory medication
The Sham Control group undergo an upper endoscopy procedure with sizing of the esophageal diameter (a component of the ablation procedure steps, deemed the sham procedure) plus standard anti-secretory drug therapy (Proton pump inhibitor, PPI)
Columbia University Medical Center, New York
Thomas Jefferson University, Philadelphia
UNC Center for Functional GI & Motility Disorders, Chapel Hill
Medical University of South Carolina, Charleston
Mayo Clinic - Jacksonville, Jacksonville
Gastrointestinal Associates, Knoxville
University Hospitals of Cleveland, Cleveland
Cleveland Clinic, Cleveland
Mayo Clinic Rochester, Rochester
Washington University School of Medicine, St Louis
University of Kansas School of Medicine - Veterans Affairs Medical Center, Kansas City
VAMC Dallas, Dallas
Mayo Clinic Scottsdale, Scottsdale
University of Arizona, VAMC, Tucson
UC Irvine Medical Center, Orange
Oregon Health Sciences University, Portland
Tacoma Digestive Disease Research Center, Tacoma
Harvard, VA Boston Healthcare W Roxbury, West Roxbury
Dartmouth-Hitchcock Medical Center, Lebanon
Lead Sponsor
Collaborators (1)
AstraZeneca
INDUSTRY
Medtronic - MITG
INDUSTRY